Mike Havrilla

13 Extreme FDA Trades

Jimmy,

It doesn't matter, the small/micro-cap companies still tend to run-up going into their FDA decisions or panel meetings.

Mike


On Jun 03 01:32 PM jimmy46 wrote:

> Almost all these drugs are "ME TOO" drugs,
> copies of something already on the market and have little chance
> of being a big earner.
>
> The antibiotic by ADLS, I'm not familiar with, but assume it's a
> ME TOO also.
>
> One of the cancer drugs has so many restrictions that only a few
> hundred people a year would take it even if it's approved.
>
> That leaves one cancer drug that might, might, be a winner,
> but cancer drugs have a history of disappointing,
> so a roll at the craps table would probably be a more likely winner.

13 Extreme FDA Trades

Pete,

There is no need to hold the extreme FDA trade stocks thru their actual decision dates or advisory panel meetings -- you can take advantage of the run-up as the decision/meeting dates approach with very little risk and still nice upside.

Mike


On Jun 03 04:44 AM PeteK wrote:

> These are all Big Gambles indeed.
> But still better than going to the casinos.

13 Extreme FDA Trades

Steve,

DSCO has not provided any public update as of yet, but the stock is trading down about 8% today at the open.

Mike


On Jun 03 07:58 AM User 416278 wrote:

> Hi Mike,
>
> Thanks for the article. In your previous extreme trade article, DSCO
> was stated to have an end-of-review meeting on 2 June 09.
> I was wondering why wasn't there any price action on this stock?
>
>
> Thanks!
>
> Steve

Trading FDA Decisions: 14 Candidates

check out this article for SVNT update:
seekingalpha.com/artic...




On Mar 16 02:18 PM truthiac wrote:

> You could add the PDUFA date of August 1, 2009, for Savient Pharmaceuticals,
> Inc.'s (seekingalpha.com/symbo...) pegloticase for treatment-failure
> gout. Since SVNT is a one-product candidate company, a major impact
> can be expected.